(lp0
S'SciClone Pharmaceuticals: Beyond The Death Of A Sales Process Seeking Alpha - Feb 2, 2017 SciClone Pharmaceuticals  is a revenue-generating pharmaceutical company with a portfolio of HBV/HCV, oncology, anti-infection and cardiovascular drug candidates.'
p1
aS"Why SciClone Pharmaceuticals, Inc. Is Surging Higher Motley Fool - Mar 12, 2015 Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis."
p2
aS'SciClone To Present At Needham Healthcare Conference On April 4, 2017 PR Newswire  - Mar 27, 2017 FOSTER CITY, Calif., March 27, 2017 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.  today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 16th Annual Needham&nbsp;...'
p3
aS'Narrowing in on the Numbers for SciClone Pharmaceuticals, Inc.  The Standard - 15 hours ago Looking at shares of SciClone Pharmaceuticals, Inc. , the company has an EV  of 370362.'
p4
aS"Why SciClone Pharmaceuticals Is Soaring Today Motley Fool - Nov 10, 2015 So what: SciClone Pharmaceuticals' Zadaxin is an immune stimulating drug that is used to treat hepatitis B. The drug, which isn't available in the United States, is sold primarily in China, which is home to roughly one third of the globe's hepatitis B ..."
p5
aS"SciClone Announces Progress In Advancing Clinical Pipeline For China ... PR Newswire  - Sep 26, 2016 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.  today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China."
p6
aS'SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG ... PR Newswire  - Nov 14, 2016 FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and&nbsp;...'
p7
aS'Stonepine Capital Management, LLC Buys Recro Pharma, SciClone Pharmaceuticals ... Nasdaq - Mar 22, 2017 Stonepine Capital Management, LLC initiated holdings in SciClone Pharmaceuticals Inc. The purchase prices were between $8.65 and $10.8, with an estimated average price of $10.'
p8
aS'SciClone Announces Final Resolution With The Securities And Exchange ... PR Newswire  - Feb 4, 2016 FOSTER CITY, Calif., Feb. 4, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today announced it has entered into a settlement agreement with the United States Securities and Exchange Commission  fully&nbsp;...'
p9
aS"Did SciClone Pharmaceuticals Inc  Create Value For Shareholders Over The ... Simply Wall St - Mar 6, 2017 SciClone Pharmaceuticals Inc  delivered a 19.7% ROE over the past year; however, the figure is only significant when we compare it to returns from assets with similar risk profile: the industry average, which stood at 27.38% in the same ...SciClone Pharmaceuticals'  CEO Friedhelm Blobel on Q4 2016 Results ... - Seeking AlphaInsider Trading at SciClone Pharmaceuticals Inc.? - Sports Perspectives"
p10
a.